Corvus Pharmaceuticals, Inc. (CRVS)

US — Healthcare Sector

Peers: MREO TERN PDSB INZY HOOK XFOR DAWN ABOS

Automate Your Wheel Strategy on CRVS

With Tiblio's Option Bot, you can configure your own wheel strategy including CRVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol CRVS
Rev/Share 0.0
Book/Share 0.6839
PB 5.7906
Debt/Equity 0.0234
CurrentRatio 4.9026
ROIC -0.6184

MktCap 305373816.0
FreeCF/Share -0.3961
PFCF -10.6901
PE -6.8992
Debt/Assets 0.0194
DivYield 0
ROE -1.1379

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 2
D/E Score 3

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
Initiation	CRVS	H.C. Wainwright	--	Buy	--	$11	Jan. 2, 2025

News

3 Penny Stocks Wall Street Sees With 243% Upside

CRVS, HIVE, TERN
Published: June 11, 2025 by: 24/7 Wall Street
Sentiment: Positive

“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.

image for news 3 Penny Stocks Wall Street Sees With 243% Upside

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript

CRVS
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, Investor Relations Leiv Lea - Chief Financial Officer Richard Miller - Chief Executive Officer Conference Call Participants Aydin Huseynov - Ladenburg Graig Suvannavejh - Mizuho Securities Li Watsek - Cantor Jeff Jones - Oppenheimer Roger Song - Jefferies Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.

image for news Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript

Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

CRVS
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Positive

Corvus Pharmaceuticals' leading drug candidate is Soquelitinib, which has broad potential across PTCL, atopic dermatitis, and ALPS. Unfortunately, it seems Corvus' early AD data might have disappointed investors (at least initially). Still, Soquelitinib's promising Phase 3 PTCL trial results are due late 2026. Its PFS metrics might help it to differentiate from other standard chemotherapy treatments.

image for news Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials

Corvus Pharmaceuticals: Now At Cruising Altitude

CRVS
Published: March 28, 2025 by: Seeking Alpha
Sentiment: Positive

Corvus Pharmaceuticals' stock has experienced volatility due to mixed clinical data, particularly from their lead asset soquelitinib's Phase 1 trial in atopic dermatitis. The company has promising developments, including a Phase 2 trial for autoimmune lymphoproliferative syndrome and potential solid tumor trials, but current data is inconclusive. Significant shareholder activity, including warrant exercises, has impacted stock price and ownership dynamics, with potential future dilution if more shares are issued.

image for news Corvus Pharmaceuticals: Now At Cruising Altitude

Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

CRVS
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Neutral

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q4 2024 Earnings Conference Call March 25, 2025 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - CFO Richard Miller - CEO Conference Call Participants Jeff Jones - Oppenheimer Aydin Huseynov - Ladenburg Thalmann Cha Cha Yang - Jefferies Daniel Bronder - Cantor Sean Lee - H.C. Wainwright Operator Good afternoon, everyone.

image for news Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

CRVS
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum

image for news Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

About Corvus Pharmaceuticals, Inc. (CRVS)

IPO Date 2016-03-23
Website https://www.corvuspharma.com
Industry Biotechnology
CEO Dr. Richard A. Miller M.D.
Employees 31

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.